Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

open", "step towards", "planned", "believes", "expected", "developing", or variations thereon, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation, the Company's need for additional capital, which may not be available in a timely manner or at all and which, if not obtained, will have a material adverse impact on the Company and its ability to continue; uncertainty whether Topical Interferon Alpha-2b or L-DOS47 will be successfully developed and commercialized as a drug or at all; the need for additional clinical trials, the occurrence and success of which cannot be assured; uncertainty whether planned clinical trials will occur as expected or whether such trials, as well as the ongoing clinical trial in Sweden and Germany, will be successful; product liability and insurance risks; research and development risks, the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, including its latest Annual Information Form, at http://www.sedar.com, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the beliefs, opinio
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 21, 2014  The element of ... emerging diseases, i.e., they strike without warning. Until now, ... warning of a viral outbreak, resulting in suboptimal responses ... Ebola currently. Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... has now been removed because virus gene structural changes ...
(Date:11/21/2014)... San Diego, CA (PRWEB) November 20, 2014 ... has extended their Sartorius Entris Balance promotion . ... for customers seeking a durable, high accuracy, and easy-to-maintain ... and made in Germany. It was designed to help ... is affordable and a balance that is very durable. ...
(Date:11/21/2014)... Fayetteville, Arkansas (PRWEB) November 20, 2014 ... partners, Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, ... equipment, announced that they have been selected to ... City of Fayetteville, Arkansas Paul R. Noland Wastewater ... feature BlueInGreen’s patented HyDOZ® gas dissolution ...
(Date:11/21/2014)... /CNW/ - Aequus Pharmaceuticals Inc. (the "Company" or ... closed a brokered private placement offering (the "Brokered ... Cormark Securities Inc. and Clarus Securities Inc. acted ... a syndicate of agents that also included Wolverton ... "Agents"). Concurrently with the Brokered Offering, the Company ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3
... , ... , GE Healthcare, The Maynard Centre, Cardiff, UK , ... siRNA methodologies and the development of high-throughput image analysis platforms such as ... proteins. Here, we describe the application of two stable cell lines expressing ...
... Birnboim , DNA Genotek, Ottawa, Ontario, Canada , ... yields than other oral, collection methods. The median yield of DNA ... swabs may yield as little as 1.9 g of DNA. , ... , The number of studies collecting genomic DNA from a large ...
... Adrian R. Elliott, Peer M. Schenk and Christopher P.L. ... , , ... Protein (GFP) from Aequorea victoria is a useful , ... emitted is easy to detect and requires no substrate or ...
Cached Biology Technology:siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 2siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 3siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 4siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 5siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 6siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 7DNA Yield with Oragene 2Quantitative Analysis of GFP in Plant Extracts Using the VersaFluor Fluorometer System 2Quantitative Analysis of GFP in Plant Extracts Using the VersaFluor Fluorometer System 3
(Date:11/3/2014)... Center study published in this month,s ... the activity of a recently discovered communication molecule of ... has been known to limit inflammation and the current ... IL-37 inhibits the ability of the immune system to ... that underlies IL-37,s effect on the immune system now ...
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
(Date:11/2/2014)... NEW ORLEANS, LA (2 November 2014)—In support of a ... the Bill & Melinda Gates Foundation today announced an ... PATH Malaria Vaccine Initiative (MVI) in building new vaccines ... and help realize the "accelerating to zero" agenda. Such ... providing what could be called an "immunological bed net." ...
Breaking Biology News(10 mins):PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... has created a compound that prevents replication of the virus ... the disease. "The outbreak of SARS in 2003 led ... is currently no treatment," said Arun Ghosh, the Purdue professor ... currently a threat, there is the concern that SARS could ...
... and receiving text messages through their cell phones sometimes ... a new study from the University of North Carolina at ... children,s chances of becoming overweight or obese later in life, ... Recent studies show that approximately 19 percent of ...
... team of scientists using optical probes means that changes ... seen in a completely different light. Prof David ... experts from Glasgow University, and a team of international ... that light was emitted by optical probes during a ...
Cached Biology News:Purdue researcher invents molecule that stops SARS 2Purdue researcher invents molecule that stops SARS 3UNC study: Text messaging may help children fight off obesity 2UNC study: Text messaging may help children fight off obesity 3Luminescence shines new light on proteins 2
... Post-Labeling Reactive Dye Pack, 12 x ... specifically optimized for microarray labeling.Higher reactivity ... reactive dye per vial, at > ... individually dispensed, and packed in foil ...
... Kit with CyScribe GFX Purification Kit, ... purification of Cy3- and Cy5-labeled cDNA.Optimized ... cDNA labeling and purification.Flexible and optimized ... labeling reactions with either Cy3- or ...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
NORMAL DONOR DONKEY SERUM...
Biology Products: